Fig. 6: Macaque ex vivo explant SHIV challenges.

a mRNAs encoding each antibody were delivered intravaginally into rhesus macaques using an aerosolizer (n = 2 per group). Cervicovaginal tissue biopsies were collected 24 h post-administration and subsequently infected with different SHIV strains. Untreated explants were served as a negative control. Tissue culture media were collected on days 4, 7, and 10, and the viral replication in the biopsies was determined using SIV p27 antigen capture assays. Created in BioRender. Santangelo, P. (2025) https://BioRender.com/u70z502. b Efficacy of tissue protection via IgG co-expression and J3-VHH-Fc against SHIV strains from clade A, B, and C. The mRNA dose was 1 mg, except for group 4, which received 3 mg. (dpi: days post-infection) c Efficacy of tissue protection via SC-PGT121 with various isotypes against SHIVs from clades B and C. All groups received 1 mg doses. d Efficacy of co-expressed, isotype-modified SC-PGT121 and VRC07 in protecting tissues against SHIVs from clades A, B, C, and AE. All groups received 1 mg doses. The lower detection limit of the assay is 31.25 pg/mL (dashed vertical line). The p27 values shown for each collection represent the amount of viral replication which occurred between the successive collections.